Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
Open Access
- 22 August 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 3 (8) , 9754-9769
Abstract
Combretastatin (CA-4) and its analogues are undergoing several clinical trials for treating different types of tumors. In this work, the antiproliferative activity of a series of 2-aminoimidazole-carbonyl analogs of clinically relevant combretastatins A-4 (CA-4) and A-1 was evaluated using a cell-based assay. Among the compounds tested, C-13 and C-21 displayed strong antiproliferative activities against HeLa cells. C-13 inhibited the proliferation of lung carcinoma (A549) cells more potently than combretastatin A-4. C-13 also retarded the migration of A549 cells. Interestingly, C-13 displayed much stronger antiproliferative effects against breast carcinoma and skin melanoma cells compared to noncancerous breast epithelial and skin fibroblast cells. C-13 strongly disassembled cellular microtubules, perturbed the localization of EB1 protein, inhibited mitosis in cultured cells, and bound to tubulin at the colchicine site and inhibited the polymerization of reconstituted microtubules in vitro. C-13 treatment increased the level of reactive oxygen species and induced apoptosis via poly(ADP-ribose) polymerase-cleavage in HeLa cells. The results revealed the importance of the 2-aminoimidazole-carbonyl motif as a double bond replacement in combretastatin and indicated a pharmacodynamically interesting pattern of H-bond acceptors/donors and requisite syn-templated aryls.Keywords
Funding Information
- Council of Scientific and Industrial Research, India
- University Grants Commission
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Science and Technology, Ministry of Science and Technology, India
- Wadhwani Research Centre for Bioengineering, Indian Institute of Technology Bombay
This publication has 92 references indexed in Scilit:
- Marine Invertebrate Natural Products that Target MicrotubulesJournal of Natural Products, 2018
- Development of combretastatins as potent tubulin polymerization inhibitorsBioorganic Chemistry, 2017
- Anti-mitotic agents: Are they emerging molecules for cancer treatment?Pharmacology & Therapeutics, 2017
- Anti-Microtubule Drugs2016
- Natural Products as Sources of New Drugs from 1981 to 2014Journal of Natural Products, 2016
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- Microtubule assembly dynamics: An attractive target for anticancer drugsIUBMB Life, 2008
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Combretastatin A-4 Analogues as Antimitotic Antitumor AgentsCurrent Medicinal Chemistry, 2003
- Antineoplastic Agents, 122. Constituents of Combretum caffrumJournal of Natural Products, 1987